BioWorld Asia

March 14, 2007

Oxford BioMedica Buys Oxxon, In Share Offering Valued At £16M

LONDON - Oxford BioMedica plc is acquiring its fellow immunotherapy specialist Oxxon Therapeutics Ltd. in an all-paper deal that values Oxxon at £12 million (US$23.3 million). In addition to six clinical stage products, the deal brings Oxford BioMedica £3 million in cash. (BioWorld International) Read More

Early Data Open New Market For AM-Pharma's Lead Drug

Protein Fragment Offers Hope For New Cancer-Killing Agent

EU Battle Lines Harden As Biotech Manifesto' Sent Back

BioAlliance, Spepharm Partner In Deal To Market Loramyc

NovaThera Expanded Deal Moves Toward Artificial Lung

Transgene Reports Net '06 Loss But Expects Busy Year Ahead

TopoTarget In-Licenses Novartis Antibody Fragment For Cancer

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...